Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Assessing the Importance of Conditioning Regimen, Donor Choice, and Tyrosine Kinase Inhibitor Use

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-141294

Published: 2020

Journal Articles

Haploidentical Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with Myelofibrosis: A Multi-Institutional Experience

Siddharth Jayant Kunte, MD, Lisa Rybicki, MS, Auro Viswabandya, MD, Asad Bashey, MD PhD, Madiha Iqbal, MBBS, Michael R. Grunwald, MD, Bhagirathbhai Dholaria, MBBS, Hany Elmariah, MDMS, Michael Ozga, MD, Anurag K. Singh, MD, Sameem Abedin, MD, Vikas Gupta, MD FRCP, FRCPath, Amy E. DeZern, MD, Richard J. Jones, MD, Aaron T. Gerds, MDMS, Tania Jain, MD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-136622

Published: 2020

Journal Articles

Reduced-Intensity Induction with Dasatinib Vs. Hypercvad + 2 nd Generation TKIs with MRD-Guided Follow-up Therapy Leads to Comparable Rates of MRD-Negative Remission While Reducing Transfusions and Neutropenia in Ph+ ALL

Blood (2020) 136 (Supplement 1): 42–44.

https://doi.org/10.1182/blood-2020-141264

Published: 2020

Journal Articles

DNMT3A clonal Hematopoiesis in Older Donors Is Associated with Improved Survival in Recipients after Allogeneic Hematopoietic Cell Transplant

Christopher J. Gibson, MD, Haesook T. Kim, PhD, H. Moses Murdock, MD, Bryan Hambley, MD, Lin Zhao, MD, Lisa Green, PhD, Mark Fleharty, Brendan Blumenstiel, Carrie Cibulskis, BSc, Christopher D Gocke, MD, Sarah Nikiforow, MD PhD, Amy E. DeZern, MD, Vincent T. Ho, MD, Richard J. Jones, MD, Niall Lennon, PhD, Jerome Ritz, MD, Robert J. Soiffer, MD, Lukasz P. Gondek, MDPhD, R. Coleman Lindsley, MD PhD

Blood (2020) 136 (Supplement 1): 26.

https://doi.org/10.1182/blood-2020-142925

Published: 2020

Journal Articles

Allogeneic Blood or Marrow Transplantation (BMT) with Post-Transplantation Cyclophosphamide (PTCy) Based Graft Versus Host Disease (GVHD) Prophylaxis for Myelodysplastic Syndrome/ Myeloproliferative Neoplasm-Overlap Syndromes (MDS/MPN)

Theodoros Karantanos, MDPhD, Hua-Ling Tsai, ScM, Lukasz P. Gondek, MDPhD, Mark Levis, MD PhD, Margaret M. Showel, MD, Amy E. DeZern, MD, Ivana Gojo, MD, Ravi Varadhan, PhD, Richard J. Jones, MD, Tania Jain, MD

Blood (2020) 136 (Supplement 1): 40.

https://doi.org/10.1182/blood-2020-138671

Published: 2020

Journal Articles

Transplant Outcomes for IDH-Mutated AML: Good Outcomes Thanks to Keeping Good Company

Alexander Joseph Ambinder, MDMPH, Matthew L Smith, Ravi Varadhan, PhD, Amy E. DeZern, MD, Mark Levis, MD PhD, Gabriel Ghiaur, MD PhD, Richard J. Jones, MD, B. Douglas Smith, MD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-141493

Published: 2020

Journal Articles

The Path to Cure: Using Haploidentical (haplo) Donors and High-Dose Post-Transplant Cyclophosphamide (PTCy) for Treatment-Naïve and Refractory Severe Aplastic Anemia (SAA)

Amy E. DeZern, MD, Marianna Zahurak, MS, Kenneth R. Cooke, MD, David Margolis, MD, Richard J. Jones, MD, Robert A. Brodsky, MD

Blood (2019) 134 (Supplement_1): 147.

https://doi.org/10.1182/blood-2019-121900

Published: 2019

Journal Articles

A Phase IB Study of Blinatumomab (blina) in Patients with B Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or Marrow Transplant (allo-BMT) Remission Maintenance

Jonathan Webster, MD, Richard F. Ambinder, MD, Richard J. Jones, MD, Nina D. Wagner-Johnston, MD, Gabrielle T. Prince, MD, Audra Shedeck, CRNP, Amanda Blackford, MS, Leo Luznik, MD, Ivana Gojo, MD

Blood (2019) 134 (Supplement_1): 778.

https://doi.org/10.1182/blood-2019-128255

Published: 2019

Journal Articles

Shortened Immunosuppression Following Peripheral Blood (PB) Haploidentical (haplo) Transplantation with Post-Transplant Cyclophosphamide (PTCy) Is Associated with Tolerable Rates of Graft-Vs-Host Disease (GVHD)

Amy E. DeZern, MD, Marianna Zahurak, MS, Javier Bolanos-Meade, MD, Richard J. Jones, MD

Blood (2019) 134 (Supplement_1): 3320.

https://doi.org/10.1182/blood-2019-122762

Published: 2019

Journal Articles

Cytomegalovirus Reactivation in Haploidentical Blood or Marrow Transplant (BMT) Using Post-Transplant Cyclophosphamide (PTCy) Is Associated with Higher Non-Relapse-Related Mortality, Despite Rarity of Disease

Maria Veronica Dioverti, MD, Chiung-Yu Huang, PhD, Megan Morales, MD, Na Lu, Willa Cochran, NP, Douglas Gladstone, MD, Darin Ostrander, PhD, Robin Avery, MD, Richard J. Jones, MD, Richard F Ambinder, MD, Kieren Marr, MD

Blood (2018) 132 (Supplement 1): 2096.

https://doi.org/10.1182/blood-2018-99-119603

Published: 2018

Journal Articles

Complete Remissions Post Infusion of Multiple Tumor Antigen Specific T Cells for the Treatment of High Risk Leukemia and Lymphoma Patients after HCT

Blood (2017) 130 (Supplement 1): 4516.

https://doi.org/10.1182/blood.V130.Suppl_1.4516.4516

Published: 2017

Journal Articles

The Fountain of Youth: Outcomes of Nonmyeloablative (NMA), HLA-Haploidentical Related (Haplo) Bone Marrow Transplantation (BMT) with Post-Transplantation Cyclophosphamide (PTCy) Best with Younger Donors Regardless of Relationship to Patient

Clio E Franklin, MBBS, BSc, MRCP, Margaret M. Showel, MD, Hua-Ling Tsai, ScM, Ravi Varadhan, PhD, Shannon R. McCurdy, MD, Douglas E. Gladstone, MD, Richard J. Jones, MD, Amy E. DeZern, MD

Blood (2017) 130 (Supplement 1): 849.

https://doi.org/10.1182/blood.V130.Suppl_1.849.849

Published: 2017

Journal Articles

Grade II Acute Gvhd Improves Progression-Free Survival after Myeloablative HLA-Matched Bone Marrow Transplant with Posttransplantation Cyclophosphamide

Shannon R. McCurdy, MD, Christopher G. Kanakry, MD, Hua-Ling Tsai, ScM, Javier Bolaños-Meade, MD, Ephraim J. Fuchs, MD MBA, Gary Rosner, ScD, Richard J. Jones, MD, Leo Luznik, MD

Blood (2017) 130 (Supplement 1): 216.

https://doi.org/10.1182/blood.V130.Suppl_1.216.216

Published: 2017

Journal Articles

Immunoglobulin Heavy Chain Variable Region (IgHV) Unmutated, but Not Mutated, Chronic Lymphocytic Leukemia (CLL) Arises in a CD34+ Progenitor

Brandy Perkins, Margaret M. Showel, MD, Laura Schoch, MS, NP, Philip Imus, MD, Gabriel Ghiaur, MD PhD, Douglas E. Gladstone, MD, Richard J. Jones, MD

Blood (2017) 130 (Supplement 1): 1709.

https://doi.org/10.1182/blood.V130.Suppl_1.1709.1709

Published: 2017

Journal Articles

FLT3 ITD AML Outcomes Are Impacted By Exposure to One Cycle of Cytarabine Based Consolidation, Pre- and Post-Transplant TKI Therapy, and Presence of Minimal Residual Disease (MRD) Prior to Allogeneic Blood or Marrow Transplant

Blood (2017) 130 (Supplement 1): 2593.

https://doi.org/10.1182/blood.V130.Suppl_1.2593.2593

Published: 2017

Journal Articles

Bone Marrow Stroma Protects FLT3 Acute Myeloid Leukemia (AML) through CYP3A4-Mediated Drug Metabolization of FLT3 Tyrosine Kinase Inhibitors (TKIs)

Yu-Ting Chang, MS, Daniela Hernandez, MD, Gabriel Ghiaur, MD PhD, Mark J. Levis, MD, Richard J. Jones, MD

Blood (2017) 130 (Supplement 1): 2519.

https://doi.org/10.1182/blood.V130.Suppl_1.2519.2519

Published: 2017

Journal Articles

The Cell of Origin in NPM1 Positive Acute Myeloid Leukemia (AML) Is Prognostic

Mark Iscoe, BA, Kelly J Norsworthy, MD, Gabriel Ghiaur, MD PhD, B. Douglas Smith, Christopher Gocke, MD, Richard J Jones, MD

Blood (2016) 128 (22): 1690.

https://doi.org/10.1182/blood.V128.22.1690.1690

Published: 2016

Journal Articles

A Randomized Phase II Trial of Interferon (IFN)/GM-CSF Versus K562/GM-CSF Vaccination in Chronic Phase CML Patients on Frontline Tyrosine Kinase Inhibitor (TKI) Therapy: Potential of IFN to Enhance Molecular Remissions

Jonathan Allen Webster, MD, Anna Ferguson, BSN, RN, Christopher Gocke, MD, Richard J Jones, MD, Hyam Levitsky, MD, B. Douglas Smith, MD

Blood (2016) 128 (22): 3088.

https://doi.org/10.1182/blood.V128.22.3088.3088

Published: 2016

Journal Articles

Second Blood or Marrow Transplant (BMT) for Relapse: Mismatch Haplotype Switch May Improve Outcome

Philip H Imus, MD, August R Dietrich, MD, Amanda Blackford, ScM, Robert A. Brodsky, MD, Heather J. Symons, Kenneth Cooke, MD, Richard J Jones, MD, Javier Bolaños-Meade, MD

Blood (2016) 128 (22): 2252.

https://doi.org/10.1182/blood.V128.22.2252.2252

Published: 2016

Journal Articles

Tumor Antigen Vaccination of Donors to Augment Graft-Versus-Tumor Effects after Allogeneic Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide

Han-Hsuan Fu, PhD, Jie Wang, MD, Jie Fu, MS, Richard J Jones, MD, Hyam Levitsky, MD, Ephraim J. Fuchs, MD

Blood (2016) 128 (22): 499.

https://doi.org/10.1182/blood.V128.22.499.499

Published: 2016

NARROW

Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Assessing the Importance of Conditioning Regimen, Donor Choice, and Tyrosine Kinase Inhibitor Use

Haploidentical Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with Myelofibrosis: A Multi-Institutional Experience

Reduced-Intensity Induction with Dasatinib Vs. Hypercvad + 2 nd Generation TKIs with MRD-Guided Follow-up Therapy Leads to Comparable Rates of MRD-Negative Remission While Reducing Transfusions and Neutropenia in Ph+ ALL

DNMT3A clonal Hematopoiesis in Older Donors Is Associated with Improved Survival in Recipients after Allogeneic Hematopoietic Cell Transplant

Allogeneic Blood or Marrow Transplantation (BMT) with Post-Transplantation Cyclophosphamide (PTCy) Based Graft Versus Host Disease (GVHD) Prophylaxis for Myelodysplastic Syndrome/ Myeloproliferative Neoplasm-Overlap Syndromes (MDS/MPN)

Transplant Outcomes for IDH-Mutated AML: Good Outcomes Thanks to Keeping Good Company

The Path to Cure: Using Haploidentical (haplo) Donors and High-Dose Post-Transplant Cyclophosphamide (PTCy) for Treatment-Naïve and Refractory Severe Aplastic Anemia (SAA)

A Phase IB Study of Blinatumomab (blina) in Patients with B Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or Marrow Transplant (allo-BMT) Remission Maintenance

Shortened Immunosuppression Following Peripheral Blood (PB) Haploidentical (haplo) Transplantation with Post-Transplant Cyclophosphamide (PTCy) Is Associated with Tolerable Rates of Graft-Vs-Host Disease (GVHD)

Cytomegalovirus Reactivation in Haploidentical Blood or Marrow Transplant (BMT) Using Post-Transplant Cyclophosphamide (PTCy) Is Associated with Higher Non-Relapse-Related Mortality, Despite Rarity of Disease

Complete Remissions Post Infusion of Multiple Tumor Antigen Specific T Cells for the Treatment of High Risk Leukemia and Lymphoma Patients after HCT

The Fountain of Youth: Outcomes of Nonmyeloablative (NMA), HLA-Haploidentical Related (Haplo) Bone Marrow Transplantation (BMT) with Post-Transplantation Cyclophosphamide (PTCy) Best with Younger Donors Regardless of Relationship to Patient

Grade II Acute Gvhd Improves Progression-Free Survival after Myeloablative HLA-Matched Bone Marrow Transplant with Posttransplantation Cyclophosphamide

Immunoglobulin Heavy Chain Variable Region (IgHV) Unmutated, but Not Mutated, Chronic Lymphocytic Leukemia (CLL) Arises in a CD34+ Progenitor

FLT3 ITD AML Outcomes Are Impacted By Exposure to One Cycle of Cytarabine Based Consolidation, Pre- and Post-Transplant TKI Therapy, and Presence of Minimal Residual Disease (MRD) Prior to Allogeneic Blood or Marrow Transplant

Bone Marrow Stroma Protects FLT3 Acute Myeloid Leukemia (AML) through CYP3A4-Mediated Drug Metabolization of FLT3 Tyrosine Kinase Inhibitors (TKIs)

The Cell of Origin in NPM1 Positive Acute Myeloid Leukemia (AML) Is Prognostic

A Randomized Phase II Trial of Interferon (IFN)/GM-CSF Versus K562/GM-CSF Vaccination in Chronic Phase CML Patients on Frontline Tyrosine Kinase Inhibitor (TKI) Therapy: Potential of IFN to Enhance Molecular Remissions

Second Blood or Marrow Transplant (BMT) for Relapse: Mismatch Haplotype Switch May Improve Outcome

Tumor Antigen Vaccination of Donors to Augment Graft-Versus-Tumor Effects after Allogeneic Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only